E. Seja

发表

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

J. Sosman, A. Ribas, Douglas B. Johnson, 2016, Cell.

PD-1 blockade induces responses by inhibiting adaptive immune resistance

R. Emerson, C. Harview, A. Ribas, 2014, Nature.

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

T. Graeber, T. Schumacher, B. Comin-Anduix, 2016, The New England journal of medicine.

Erratum: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell (2016) 165(1) (35–44)(S009286741630215X)(10.1016/j.cell.2016.02.065))

J. Sosman, A. Ribas, Douglas B. Johnson, 2017 .

Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies.

B. Comin-Anduix, A. Ribas, J. Reuben, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial

S. Raman, A. Ribas, J. Weber, 2011, Clinical Cancer Research.

Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.

A. Ribas, L. Gordon, J. Gómez-Navarro, 2007, American journal of ophthalmology.

T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.

A. Ribas, L. Butterfield, W. McBride, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy

J. Wargo, A. Ribas, L. Butterfield, 2004, Journal of immunotherapy.

Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays

B. Comin-Anduix, A. Ribas, A. Gualberto, 2006, Clinical Cancer Research.

A methods study to define the performance specifications of MHC tetramer assays for immune monitoring of tumor immunotherapy.

B. Comin-Anduix, A. Ribas, A. Gualberto, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PD-1 Blockade Expands Intratumoral Memory T Cells

Dana Pe'er, Antoni Ribas, Juliet Frederiksen, 2016, Cancer Immunology Research.

Long term Survival with CTLA-4 blockade Using Tremelimumab

A. Ribas, L. Camacho, Kevin B. Kim, 2016 .

Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma

A. Ribas, J. Reuben, L. Camacho, 2005 .

A Phase I/II Trial Testing Immunization of Hepatocellular Carcinoma Patients with Dendritic Cells Pulsed with Four α-Fetoprotein Peptides

A. Ribas, L. Butterfield, R. Finn, 2006, Clinical Cancer Research.

A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.

A. Ribas, L. Butterfield, R. Finn, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

B. Comin-Anduix, A. Ribas, J. Reuben, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

K. Cornetta, A. Ishiyama, J. Heath, 2014, Clinical Cancer Research.

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

T. Graeber, L. Diaz, B. Comin-Anduix, 2017, Cancer discovery.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

J. Sosman, A. Ribas, Douglas B. Johnson, 2017, Cell.

Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma

A. Ribas, L. Butterfield, J. Economou, 2008, Journal of immunotherapy.

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

B. Comin-Anduix, A. Ribas, L. Camacho, 2008, Journal of Translational Medicine.

1 PD-1 blockade expands intratumoral T memory cells

D. Pe’er, A. Cornish, B. Comin-Anduix, 2016 .

CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans

A. Ribas, A. Cochran, Stephen Mok, 2011, Clinical Cancer Research.

Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

F. Marincola, B. Comin-Anduix, A. Ribas, 2009, Clinical Cancer Research.

Cancer Therapy: Clinical Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

F. Marincola, B. Comin-Anduix, A. Ribas, 2009 .

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

A. Ribas, L. Camacho, Kevin B. Kim, 2015, European journal of cancer.

Imaging of CTLA4 Blockade–Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab

A. Ribas, J. Czernin, C. Radu, 2010, Journal of Nuclear Medicine.

The effects of a high‐fat meal on single‐dose vemurafenib pharmacokinetics

A. Ribas, A. Joe, G. Daniels, 2014, Journal of clinical pharmacology.

CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans

A. Ribas, A. Cochran, Stephen Mok, 2011, Clinical Cancer Research.